Details of the Drug Combinations

General Information of This Drug (ID: DM548TK)

Drug Name

Belumosudil DM548TK

Synonyms

KD025

Indication

Disease Entry	ICD 11	Status	REF
Graft-versus-host disease	4B24	Approved	[1]
Psoriasis vulgaris	EA90	Phase 2	[2]
Rheumatoid arthritis	FA20	Phase 2	[3]
Psoriatic arthritis	FA21	Phase 1	[4]
Scleroderma	4A42	Phase 1	[4]
Systemic lupus erythematosus	4A40.0	Phase 1	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
KD025 + Panobinostat	DCJOVOX	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
------------------------------------------------------------------------------------

References

1	FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 214783.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	ClinicalTrials.gov (NCT02317627) Study of of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-Line Therapy. U.S. National Institutes of Health.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.